Drugs / ABBV-969
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06318273 | Mar 2024 → May 2027 expected | prostate carcinoma | AbbVie | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | AbbVie | Results AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline abbvie.com ↗
A first-in-human Phase 1 study ( NCT06318273 ) evaluating ABBV-969, a potential first-in-class bispecific ADC targeting PSMA/STEAP1 , in heavily pretreated patients with mCRPC, demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients with RECIST-evaluable disease. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | AbbVie | AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline abbvie.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-969 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06318273 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06318273 ↗ |